Gambro is a global medical technology company that manufactures products for dialysis treatment. The company is a global leader in developing, manufacturing and supplying products and therapies for kidney and liver dialysis, Myeloma Kidney Therapy, and other extracorporeal therapies for chronic and acute patients. Gambro was founded in Lund, Sweden in 1964 by Holger Crafoord and has around 8,000 employees, production facilities in nine countries, and sales in more than 100 countries.[1]

In September 2013, Baxter International completed its acquisition of Gambro.[2]


Professor Nils Alwall invented one of the first artificial kidneys in 1961. Three years later he met industrialist and businessman Holger Crafoord who was impressed by Alwall’s invention and felt compelled to develop and market this life-saving innovation.[3]

The development of single-use artificial kidneys began in Lund, Sweden and mass production started in 1967 with the “Ad-modum-Alwall” dialyzer. The company adopted the name Gambro, which is the abbreviation of the original Swedish company name: “Gamla Brogatans Sjukvårdsaffär Aktiebolag". Roughly translated, this means “The Old Bridge Street Medical Supplies Company". The company’s first plant outside Sweden was built in Hechingen, Germany in the 1970s. In 1983, Gambro became listed on the Stockholm Stock Exchange. On April 3, 2006, Indap AB, joint-owned by Swedish investment companies EQT and Investor AB, announced a public cash offer to the shareholders of Gambro to acquire all outstanding shares in the company. The new ownership structure of Gambro became effective in June 2006. [3]

In recent decades, Gambro’s range of products and therapies has grown - through the introduction of new products, as well as several acquisitions, such as Hospal in 1987, COBE in 1990, Teraklin in 2004 and the latest addition of CHF Solutions Inc. in 2010. CHF Solutions designs and manufactures therapies and products for treating fluid overload by means of ultrafiltration. [4]

In July 2013, Baxter International’s bid for Gambro was approved by EU antitrust regulators.[5]


Gambro has production facilities in 9 countries. The company’s newest plant is a manufacturing facility in Opelika, Alabama, USA which started production in 2009. [6] The largest manufacturing facility is located in Hechingen, Germany, employing approx. 1,380 people. The company says it focuses on bringing new innovative products and therapies to the market and today owns the rights to more than 1800 patents. Gambro has 350 R&D employees in 4 locations all over Europe. The company has offices and representatives in more than 100 countries. Around 350,000 chronic renal disease patients are treated with Gambro products every year; this is approximately one quarter of all dialysis patients worldwide.


  1. ^ Gambro (2014). "About Gambro". Gambro. Retrieved December 11, 2014. 
  2. ^ Baxter (2013). "Baxter Acquires Gambro". Baxter. Retrieved December 11, 2014. 
  3. ^ a b Lund University (2005). "Nils Alwall, the artificial kidney and Gambro". Lund University. Archived from the original on October 1, 2007. Retrieved December 11, 2014. 
  4. ^ Gambro (2014). "Aquadex FlexFlow". Gambro. Retrieved December 11, 2014. 
  5. ^ Foo Yun Chee (10 July 2013). "EU to clear Baxter's $4 billion buy of Sweden's Gambro: sources". Reuters. 
  6. ^ Sara Falligant (2014). "Opelika". Opelika-Auburn News. Retrieved December 11, 2014.